Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With CACAG Regimen vs "3+7" Regimen in Newly Diagnosed Acute Myeloid Leukemia
NCT06068621Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Overall Response Rate at 1 month. Started Mar 2023; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06068621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068621.